This ZEB2/LSD1 interaction appears to repress pro-apoptotic genes such as BIM, making ETP-ALL cells susceptible to combined treatment with LSD1 inhibitor and the BCL2 inhibitor ABT-199 or the JAK/STAT inhibitor Ruxolitinib (159). Here, ZEB2 is linked to acute lymphoblastic leukemia.